XMU-MP-1 NEW
| Price | $48 | $72 | $98 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: XMU-MP-1 | CAS No.: 2061980-01-4 |
| Purity: 99.68% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | XMU-MP-1 |
| Description | XMU-MP-1 is a reversible and selective MST1/2 kinase inhibitor, and its IC50 values for MST1 and MST2 are 71.1 nM and 38.1 nM, respectively. |
| Kinase Assay | XMU-MP-1 is dissolved in DMSO (stock concentration, 10 mM). For the in vitro kinase inhibition assays, recombinant GST-tagged MOB1a and various forms of recombinant His-tagged full-length MST1 or MST2 kinase are expressed and purified from Escherichia coli. The assays are performed with the various doses of XMU-MP-1 in the kinase assay buffer for 30 min at 30°C[1]. |
| In vitro | METHODS: HepG2 cells, mouse macrophage-like cells, human osteosarcoma, and human colorectal adenocarcinoma cells were treated with XMU-MP-1 (0-3 μM) for 15 minutes, and the phosphorylation levels were detected by western blot. RESULTS: XMU-MP-1 reduces the phosphorylation of endogenous MOB1, LATS1/2 and YAP in HepG2 cells in a dose-dependent manner. XMU-MP-1 inhibits hydrogen peroxide-stimulated phosphorylation of MOB1 and autophosphorylation of MST1/2 in mouse macrophagocyte-like cells, human osteosarcoma, and human colorectal adenocarcinoma cells. [1] |
| In vivo | METHODS: To study the effect of XMU-MP-1 on cardiac function, C57Bl/6 mice underwent transverse aortic cotation (TAC) surgery to induce cardiac hypertrophy and dysfunction. XMU-MP-1 (1 mg/kg) or solvent (DMSO) treatment was administered 3 weeks after the operation, once every 2 days for 10 consecutive days. RESULTS: The cardiac systolic function of mice treated with XMU-MP-1 was significantly improved, manifested as an increase in ejection fraction. The cross-sectional area of myocardial cells in mice treated with XMU-MP-1 decreased, and the expression of the hypertrophy marker brain natriuretic peptide (BNP) decreased. The number of TunEL-positive cardiomyocytes in the hearts of mice treated with XMU-MP-1 decreased, and the degree of fibrosis was reduced, indicating that this drug inhibited cardiomyocyte apoptosis and fibrosis. [2] METHODS: To study the ability of XMU-MP-1 in liver injury repair, XMU-MP-1 (1-3 mg/kg) was intraperitoneally injected into mouse models of acute/chronic liver injury. RESULTS: XMU-MP-1 has good pharmacokinetic characteristics in vivo and can improve the repair and regeneration ability of the intestinal tract and liver of mice. METHODS: To study the anti-tumor activity of XMU-MP-1, XMU-MP-1 was injected daily into NSG mice supplemented with estrogen. RESULTS: XMU-MP-1 significantly inhibited tumor growth in MCF-7 xenografts, and the treated xenografts showed increased nuclear localization of YAP and expression of target genes. [3] METHODS: To study the effect of XMU-MP-1 on osteoarthritis, XMU-MP-1 (1 mg/kg) was intraperitoneally injected into a mouse model of osteoarthritis for two consecutive weeks. RESULTS: XMU-MP-1 can inhibit the erosion of the articular cartilage surface and the thickening of the synovial membrane, and alleviate the symptoms of osteoarthritis. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 12.5 mg/mL (30.01 mM), Sonication is recommended. |
| Keywords | XMU-MP-1 | XMUMP1 | XMU MP 1 | MST2 | MST1 | Inhibitor | inhibit | Hippopathway | Hippo pathway | Hippo (MST) |
| Inhibitors Related | Pim1/AKK1-IN-1 | I3MT-3 | IHMT-MST1-58 | Cerdulatinib hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
![[11C]MP 10](https://img.chemicalbook.com/ProductImageEN1/2025-09/Large/09712312-be7f-49c3-8c0d-1c1690d044aa.png)
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $0.00/100mg |
VIP2Y
|
Xian confluore Biological Technology Co., Ltd.
|
2024-04-01 | |
| $4570.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY